No Data
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection
Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation
Sinopharm Hyundai: 2024 Annual Performance Forecast
2024 Annual Results Forecast
Shanghai Shyndec Pharmaceutical (600420.SH): Expected net income for the 2024 fiscal year to increase by 52.31% to 71.10% year-on-year.
On January 19, Longcaihui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that the company expects to achieve a net income of 1.054 billion to 1.184 billion yuan attributable to shareholders of the listed company in 2024, an increase of 52.31% to 71.10% year-on-year. The announcement stated that in 2024, the company will actively seize market opportunities, with increased sales of penicillin and macrolide Active Pharmaceutical Ingredients due to strong market demand. Moreover, through process innovation, strategic synergy, and procurement optimization, the company will continue to enhance quality and efficiency, leading to an improvement in the gross margin of the company's pharmaceutical intermediates and Active Pharmaceutical Ingredients business Sector year-on-year. In addition, actively respond to
Shanghai Shyndec Pharmaceutical (600420.SH): A subsidiary has passed the EU-GMP certification in Germany.
Glonghui, January 17 – Shanghai Shyndec Pharmaceutical (600420.SH) announced that its holding subsidiary, China National Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. (referred to as Zhijun), has received a GMP certificate issued by the relevant German regulatory agency (Bundesinstitutfür Arzneimittel und Medizinprodukte, referred to as BfArM). The production line in Workshop 1 of Zhijun for powder injections has successfully passed the EU-GMP compliance inspection for the first time. This certification indicates that Zhijun meets the standards for quality management systems and production environment facilities.
